Date: 2014-06-17
Type of information: Private placement
Company: Cantargia (Sweden)
Investors:
Amount: 20 MSEK
Funding type: private placement of new shares
Planned used:
Others: * On June 17, 2014, Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces that Dr. Göran Forsberg will take over the CEO position Furthermore, the company has decided to issue new shares corresponding to 20 MSEK. Cantargia continues to develop successfully and is happy to announce that Göran Forsberg has been engaged to lead the company to take it into the next important development steps. In addition the long term financial strategy is followed and the company will issue shares corresponding to 20 MSEK directed to the owners of its main shareholder, LU Bioscience AB (LU Bio). Cantargia is now entering a new phase in the company development. The lead monoclonal antibody has shown robust antitumor effects as well as solid findings supporting the mechanism of action and is entering late stage preclinical development. Cantargia now aims to increase the focus on clinical development, business development and commercial partnerships where the experience of Göran Forsberg will be of great value.
Therapeutic area: Cancer - Oncology
